terican

Last verified · v1.0

Calculator · health

Breast Cancer Recurrence Risk Calculator (10 Year)

Calculates 10-year breast cancer recurrence risk using the Nottingham Prognostic Index, receptor status, and adjuvant therapy modifiers.

FreeInstantNo signupOpen source

Inputs

Estimated 10-Year Recurrence Risk

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

Estimated 10-Year Recurrence Risk—

The formula

How the
result is
computed.

How the 10-Year Breast Cancer Recurrence Risk Calculator Works

The Nottingham Prognostic Index (NPI) Foundation

The Breast Cancer Recurrence Risk Calculator is built on the Nottingham Prognostic Index (NPI), one of the most rigorously validated prognostic tools in oncology. The core formula is:

NPI = 0.2 × S + N + G

Where S is the maximum invasive tumor diameter in centimeters, N is the lymph node stage (1 = no involved nodes, 2 = 1–3 positive nodes, 3 = 4+ positive nodes), and G is the Nottingham histologic tumor grade (1 = well differentiated, 2 = moderately differentiated, 3 = poorly differentiated). The full 10-year recurrence risk model then extends the NPI with four personalized delta adjustments:

Risk10yr = f(NPI) + ΔER + ΔHER2 + ΔTx + ΔAge

NPI Risk Categories and 10-Year Survival Benchmarks

  • Excellent (NPI ≤ 2.4): Approximately 85% 10-year survival; very low recurrence probability
  • Good (NPI 2.41–3.4): Approximately 70% 10-year survival; low-to-moderate risk
  • Moderate I (NPI 3.41–4.4): Approximately 60% 10-year survival
  • Moderate II (NPI 4.41–5.4): Approximately 45% 10-year survival
  • Poor (NPI > 5.4): Approximately 20% 10-year survival; high recurrence risk

Delta Modifiers: Personalizing the Risk Estimate

Four additional modifiers adjust the NPI baseline to reflect individual tumor biology and treatment choices:

  • ΔER — Estrogen Receptor Status: ER-positive tumors account for approximately 75% of all breast cancers. ER+ status confers a lower initial recurrence hazard but carries a persistent late-recurrence risk extending well beyond 5 years, a pattern thoroughly documented in the PMC review on evolution of breast cancer recurrence risk prediction (2024). ER-negative status correlates with an earlier but more temporally concentrated recurrence hazard.
  • ΔHER2 — HER2/neu Amplification Status: HER2-positive tumors (approximately 15–20% of cases) historically carried a substantially worse prognosis. Trastuzumab-based regimens introduced since the HERA and NSABP B-31 trials have reduced recurrence risk by up to 50% in eligible HER2+ patients, making this delta modifier among the most treatment-responsive in the model.
  • ΔTx — Adjuvant Therapy Modifiers: Endocrine therapy (tamoxifen or aromatase inhibitors for 5+ years) reduces the annual recurrence rate by approximately 40% in ER+ disease. Adjuvant chemotherapy provides an additional 20–35% proportional risk reduction across most subtypes. The model applies cumulative downward adjustments for each therapy completed, reflecting their independent and additive benefits established in EBCTCG meta-analyses.
  • ΔAge — Age at Diagnosis: Patients diagnosed under age 40 tend to present with more biologically aggressive disease, elevating their adjusted baseline risk. Patients over 70 may face competing non-cancer mortality that affects net clinical interpretation of the 10-year estimate.

Worked Clinical Example

A 48-year-old patient presents with a 2.8 cm, Nottingham grade 2, ER-positive, HER2-negative tumor with 2 positive axillary lymph nodes. She receives 5 years of letrozole and adjuvant chemotherapy.

  • NPI = 0.2 × 2.8 + 2 + 2 = 4.56 → Moderate II prognostic group (baseline ~45% 10-year survival)
  • ΔER: Favorable modifier applied for ER+ biology
  • ΔHER2: Neutral (HER2-negative, no trastuzumab modifier)
  • ΔTx: Significant downward adjustment for aromatase inhibitor plus adjuvant chemotherapy
  • ΔAge: Mild adverse adjustment for premenopausal diagnosis at 48

After all modifiers are applied, the estimated 10-year recurrence risk falls meaningfully below the Moderate II NPI baseline alone, illustrating why completed adjuvant therapy adherence is critical to long-term outcomes.

Evidence Base and Methodology

This calculator integrates the NPI framework validated across multiple prospective UK cohorts and described in the evolution of breast cancer recurrence risk prediction (PMC, 2024), with biomarker adjustments aligned to the BCSC Invasive Breast Cancer Risk Calculator (UC Davis). Receptor-weighted risk adjustments are further informed by the Magee Equations from the University of Pittsburgh Medical Center, which estimate genomic recurrence scores from pathologic variables. Treatment delta values derive from published hazard ratios in EBCTCG meta-analyses and landmark randomized trials including ATAC, BIG 1-98, and HERA.

Important Limitations

This tool provides a population-level statistical estimate for general informational and educational purposes only. It does not incorporate genomic profiling data (Oncotype DX 21-gene Recurrence Score, MammaPrint 70-gene assay, or PAM50/Prosigna), Ki-67 proliferation index, lymphovascular invasion status, or BRCA1/2 germline mutation results — all of which can meaningfully refine individual prognosis. Always consult a board-certified oncologist or breast surgeon before making any clinical decisions based on this estimate.

Reference

Frequently asked questions

What is the Nottingham Prognostic Index and how is it calculated for breast cancer?
The Nottingham Prognostic Index (NPI) is a validated scoring system combining three tumor characteristics: NPI = 0.2 x tumor size in centimeters + lymph node stage (1, 2, or 3) + histologic grade (1, 2, or 3). A score below 2.4 indicates an excellent prognostic group with roughly 85% 10-year survival, while a score above 5.4 places patients in the poor prognostic group with approximately 20% 10-year survival. The NPI was developed and validated at City Hospital Nottingham across thousands of breast cancer patients over several decades.
What does 10-year breast cancer recurrence risk actually mean?
The 10-year recurrence risk is the statistical probability that breast cancer will return — locally in the breast, regionally in nearby lymph nodes, or distantly in organs such as the liver, lungs, or bones — within 10 years of the initial diagnosis. A 15% 10-year risk means that approximately 15 out of 100 women with similar tumor characteristics and treatment history would be expected to experience a recurrence within that decade. This figure helps oncologists determine the appropriate intensity of adjuvant therapy and the frequency of long-term surveillance imaging.
How does ER-positive status affect breast cancer recurrence risk over 10 years?
ER-positive breast cancer, which accounts for approximately 75% of all cases, displays a distinct recurrence pattern: early recurrence rates within the first 5 years tend to be lower than for ER-negative disease, but ER+ tumors carry a persistent late-recurrence hazard that continues well beyond 5 years and in some cohorts extends to 20 years post-diagnosis. Completing 5 to 10 years of endocrine therapy with tamoxifen or an aromatase inhibitor reduces both early and late recurrence hazard by approximately 30 to 50%, according to Early Breast Cancer Trialists Collaborative Group (EBCTCG) meta-analyses, making adherence to endocrine therapy critically important.
Does HER2-positive breast cancer always mean a higher 10-year recurrence risk?
In the pre-targeted-therapy era, HER2-positive status (affecting 15 to 20% of breast cancers) was strongly associated with significantly worse outcomes and elevated recurrence rates. However, the addition of trastuzumab (Herceptin) to adjuvant chemotherapy demonstrated approximately 50% reduction in recurrence risk in HER2+ patients across the landmark HERA and NSABP B-31 trials. Today, with modern HER2-targeted therapy regimens — including pertuzumab and ado-trastuzumab emtansine for higher-risk disease — the prognosis for HER2+ patients has improved dramatically, and HER2+ status alone no longer automatically confers the worst 10-year risk category.
How much does adjuvant chemotherapy reduce 10-year breast cancer recurrence risk?
Adjuvant chemotherapy reduces the annual breast cancer recurrence rate by approximately 20 to 35% proportionally, which translates to an absolute 10-year risk reduction of roughly 3 to 12 percentage points depending on baseline risk level and disease subtype. According to EBCTCG meta-analyses encompassing over 100,000 patients, the relative benefit is consistent across regimens, but the absolute benefit is largest in higher-risk patients — those with node-positive disease, high-grade tumors, triple-negative, or HER2-positive subtypes. Lower-risk ER-positive patients may gain minimal absolute benefit from chemotherapy beyond endocrine therapy alone.
What factors are NOT captured by this breast cancer recurrence risk calculator?
Several clinically meaningful prognostic variables fall outside this calculator's scope. Genomic assays — including Oncotype DX (21-gene Recurrence Score), MammaPrint (70-gene assay), and PAM50/Prosigna — provide gene-expression-based risk stratification that can significantly change treatment recommendations beyond what clinical-pathologic variables alone can predict. Additional factors not modeled here include Ki-67 proliferation index, lymphovascular invasion, tumor histologic subtype (lobular versus ductal), BRCA1 and BRCA2 germline mutation status, multifocality, and contralateral breast cancer risk. Patients should discuss whether genomic testing is appropriate for their situation with a board-certified oncologist.